Charles R. Bridges, MD, ScD, HMS ‘81
Global Chief Technology Officer, Pulmonary Hypertension Therapeutic Area
Janssen Pharmaceuticals, Research and Development
Johnson & Johnson
Since January of 2018, Dr. Bridges has served as the Global Chief Technology Officer, Pulmonary Hypertension Therapeutic Area, Janssen Pharmaceuticals, where he leads the development of novel therapeutic devices and the application of advanced data sciences methods to solve problems in R&D. An important goal here is to accelerate the development of novel commercially available technologies for the early diagnosis of rare diseases including pulmonary arterial hypertension. From 2015 through January 2018, he was Global Vice President, Cardiovascular Therapeutic Area Expert for Johnson & Johnson Medical Devices, serving as the worldwide scientific lead for high-profile investments and acquisitions in the Cardiovascular and Neurovascular spaces culminating in the formation of Cerenovus, Johnson and Johnson’s neurovascular business in July 2017. Cerenovus achieved FDA approval for their mechanical thrombectomy platform in 2019, allowing for the reversal of the manifestations of ischemic stroke in a majority of patients. Cerenovus is now one of the fastest growing sectors in Johnson & Johnson Medical Devices. One of his first investments after joining Johnson & Johnson, a $40 million dollar equity investment in a Minnesota-based company, CVRx, led in August 2019 to the first ever FDA-approved neuromodulation device to treat heart failure. In total, he served as the scientific lead on half a billion dollars of investments in medical device technologies.